Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer

Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer

Abstract Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Ya‐Shang Zheng, Wu‐Hao Lin, Jun‐Quan Chen, Xiao‐Li Wei, Jia‐Qian Huang, Yu‐Hong Xu, Meng Yang, Qi‐Hua Zhang, Zhi‐Jun Zuo, Zhao‐Ying Yang, Pan Zhang, Nga Ki HONG, Lu‐Xuan Liu, Zhao‐Lei Zeng, Rui‐Hua Xu, Hui‐Yan Luo
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:MedComm
Subjects:
biomarker
blood microbiome
efficacy
immunotherapy
Lactobacillus
Online Access:https://doi.org/10.1002/mco2.70316
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy of immunotherapy combined with chemotherapy in GI cancer patients through 16S rRNA sequencing. Our findings demonstrated that lower baseline alpha diversity and specific microbial compositions, particularly lower levels of Lactobacillus, were significantly associated with longer progression‐free survival (PFS) in patients receiving immunotherapy combined with chemotherapy. Furthermore, we validated the reliability of Lactobacillus abundance as a predictor of PFS and treatment response in another independent patient cohort. Additionally, patients with increased or stable levels of Lactobacillus after immunotherapy combined with chemotherapy had superior PFS. Gavage of Lactobacillus rhamnosus (L. rhamnosus) el evated its blood level and enhanced the efficacy of immunotherapy in mouse models. Our results suggest that Lactobacillus may serve as a novel biomarker for predicting the efficacy of immunotherapy combined with chemotherapy and hold the potential as a PD‐1 antibody sensitizer.
ISSN:2688-2663

Similar Items